Patterns of Clinical Response in Patients With Alopecia Areata Treated With Ritlecitinib in the Allegro Clinical Development Programme

February 2025 in “ Journal of the European Academy of Dermatology and Venereology ”

Brett King, Paradi Mirmirani, Kristen Lo Sicco, Yuval Ramot, Rodney Sinclair, Leila Asfour, Khaled Ezzedine, C. Paul, M. Ohyama, Roger Edwards, Gianluca Bonfanti, U. Kerkmann, Dalia Wajsbrot, R. Ishowo‐Adejumo, Samuel H. Zwillich, A. Lejeune

alopecia areata ritlecitinib scalp hair loss ALLEGRO clinical development program

TLDR Ritlecitinib shows promise for treating alopecia areata, especially with early and extended treatment.

The study on alopecia areata (AA) treated with ritlecitinib in the ALLEGRO clinical development program involved 191 patients and identified six distinct response patterns over nearly 2 years. Of these patients, 45.5% achieved a response, with 93.1% maintaining it through 24 months. Factors such as female sex, less extensive scalp hair loss, and shorter duration of hair loss were linked to better responses. The study highlights the potential of ritlecitinib in treating AA, with extended treatment beyond 1 year being beneficial for some patients. Early intervention and extended treatment may improve outcomes, especially in severe cases, although further research is needed to confirm optimal timing for treatment initiation.

View this study on onlinelibrary.wiley.com →

Discuss this study in the Community →

Research cited in this study

25 / 25 results

research Efficacy and Safety of the Oral Janus Kinase 3/Tyrosine Kinase Inhibitor Ritlecitinib Over 24 Months: Integrated Analysis of the ALLEGRO Phase IIb/III and Long-Term Phase III Clinical Studies in Alopecia Areata

23 citations , October 2024 in “British Journal of Dermatology”

Ritlecitinib effectively treats alopecia areata and is safe for long-term use in people 12 and older.

Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program

research Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program

January 2024 in “American journal of clinical dermatology”

Ritlecitinib is safe and well-tolerated for treating alopecia areata in patients aged 12 and older.

research European Expert Consensus Statement on the Systemic Treatment of Alopecia Areata

4 citations , January 2024 in “JEADV. Journal of the European Academy of Dermatology and Venereology/Journal of the European Academy of Dermatology and Venereology”

Baricitinib and ritlecitinib are recommended for severe alopecia areata, with other treatments available off-label.

research Inhibition of T-Cell Activity in Alopecia Areata: Recent Developments and New Directions

4 citations , November 2023 in “Frontiers in immunology”

New treatments targeting T-cell pathways are needed for better alopecia areata management.

research Efficacy of Baricitinib in Patients with Various Degrees of Alopecia Areata Severity: Post-Hoc Analysis from BRAVE AA1 and BRAVE AA2

1 citations , September 2023 in “Dermatology and Therapy”

Baricitinib helps improve hair growth in severe alopecia, with better results in less severe cases and higher doses working faster.

Expecting Scalp Hair Regrowth During Severe Alopecia Areata Treatment with Baricitinib: Insights from Patient Trajectories in Phase III Trials

research Expecting Scalp Hair Regrowth During Severe Alopecia Areata Treatment with Baricitinib: Insights from Patient Trajectories in Phase III Trials

September 2023 in “British Journal of Dermatology”

Hair regrowth from severe alopecia areata treatment with baricitinib can vary, with faster results in those with shorter hair loss duration.

Major Improvement of Very Severe Alopecia Areata in Patients Treated With the Combination of Baricitinib and Low Doses of Corticosteroids: An Eight-Case Series

research Major Improvement of Very Severe Alopecia Areata in Patients Treated With the Combination of Baricitinib and Low Doses of Corticosteroids: An Eight-Case Series

July 2023 in “Clinical and Experimental Dermatology”

Combining baricitinib with low-dose corticosteroids significantly improved severe hair loss in eight patients.

research Efficacy and Safety of Ritlecitinib in Adults and Adolescents With Alopecia Areata: A Randomised, Double-Blind, Multicentre, Phase 2b–3 Trial

227 citations , April 2023 in “The Lancet”

Ritlecitinib effectively treats alopecia areata and is well-tolerated.

research Trends in Prevalence and Incidence of Alopecia Areata, Alopecia Totalis, and Alopecia Universalis Among Adults and Children in a US Employer-Sponsored Insured Population

75 citations , March 2023 in “JAMA Dermatology”

Alopecia areata and its severe forms are becoming more common, especially among females, adults, and people in the Northeast.

research Two Phase 3 Trials of Baricitinib for Alopecia Areata

148 citations , March 2022 in “The New England Journal of Medicine”

Baricitinib was effective in treating alopecia areata in two major trials.

research Hair Follicle Immune Privilege and Its Collapse in Alopecia Areata

134 citations , July 2020 in “Experimental dermatology”

Hair follicles are normally protected from the immune system, but when this protection fails, it can cause hair loss in alopecia areata.

research Emerging Topical and Systemic JAK Inhibitors in Dermatology

277 citations , December 2019 in “Frontiers in Immunology”

JAK inhibitors show promise for treating skin disorders like alopecia, eczema, and psoriasis.

research Targeting the Janus Kinase Family in Autoimmune Skin Diseases

124 citations , October 2019 in “Frontiers in Immunology”

Janus kinase inhibitors are promising treatments for autoimmune skin diseases like eczema and psoriasis.

research Treatment of Alopecia Areata: An Australian Expert Consensus Statement

95 citations , November 2018 in “Australasian journal of dermatology”

Alopecia areata treatment varies, with no optimal method established yet.

research Comorbidities in Alopecia Areata: A Systematic Review and Meta-Analysis

100 citations , July 2018 in “Journal of The American Academy of Dermatology”

People with alopecia areata often have other health issues like skin diseases, metabolic syndrome, stomach infections, lupus, anemia, thyroid problems, mental health issues, vitamin D deficiency, and hearing and eye problems.

research Role of Janus Kinase Inhibitors in the Treatment of Alopecia Areata

53 citations , July 2018 in “Drug design, development and therapy”

Janus kinase inhibitors show promise in treating alopecia areata but need better topical formulations.

research Tofacitinib for the Treatment of Severe Alopecia Areata and Variants: A Study of 90 Patients

238 citations , November 2016 in “Journal of The American Academy of Dermatology”

Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.

research Multiplex Matrix Network Analysis of Protein Complexes in the Human TCR Signalosome

32 citations , August 2016 in “Science Signaling”

Alopecia areata patients show unique protein activity patterns, suggesting imbalanced signaling pathways.

research Health-Related Quality of Life Among Patients With Alopecia Areata: A Systematic Review

95 citations , July 2016 in “Journal of The American Academy of Dermatology”

People with alopecia areata, a skin disease, generally have a poor quality of life, especially if more of their scalp is affected.

research The Autoimmune Basis of Alopecia Areata: A Comprehensive Review

162 citations , October 2014 in “Autoimmunity reviews”

Alopecia areata is caused by the immune system attacking hair follicles.

research Alopecia: Evaluation and Treatment

76 citations , July 2011 in “Clinical, Cosmetic and Investigational Dermatology”

The document concludes that proper diagnosis and FDA-approved treatments for different types of hair loss exist, but treatments for severe cases often fail and future improvements may focus on hair follicle stem cells.

research Prognostic Factors in Methylprednisolone Pulse Therapy for Alopecia Areata

27 citations , May 2011 in “Journal of dermatology”

Methylprednisolone pulse therapy works best for recent and specific types of severe alopecia areata.

research Alopecia Areata Update

244 citations , January 2010 in “Journal of the American Academy of Dermatology”

The document says current treatments for alopecia areata do not cure or prevent it, and it's hard to judge their effectiveness due to spontaneous remission and lack of studies.

research Intralesional Steroids for Alopecia Areata

36 citations , January 2010 in “International Journal of Trichology”

Intralesional steroids can help regrow hair in some alopecia areata patients but have side effects.

research Lymphocytes, Neuropeptides, And Genes Involved In Alopecia Areata

286 citations , August 2007 in “Journal of Clinical Investigation”

Alopecia areata is an autoimmune disease where T cells attack hair follicles.